Palbociclib free base- CAS 571190-30-2 (free base)
Palbociclib, also known as PD-0332991, is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression. Palbociclib, was approved on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor-positive advanced breast cancer.
Catalog Number: I008544
CAS Number: 571190-30-2 (free base)
PubChem Substance ID:355193459
Molecular Formula: C24H29N7O2
* For research use only. Not for human or veterinary use.
|Synonyms||PD-0332991; PD 0332991; PD0332991; Palbociclib free base, brand name: Ibrance.;6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one|
|Solubility||Soluble in DMSO, not in water|
|Storage||0 - 4 °C for short term, or -20 °C for long term|